[Skip to Content]
[Skip to Content Landing]
July 24, 1995

Liposomal Amphotericin B Therapy in Disseminated Histoplasmosis

Author Affiliations

Kiel, Germany

Arch Intern Med. 1995;155(14):1556. doi:10.1001/archinte.1995.00430140136020

The incidence of disseminated histoplasmosis in the United States is increasing, especially among immunocompromised patients.1 Conventional treatment consists of amphotericin B, whose

First Page Preview View Large
First page PDF preview
First page PDF preview